RU2014129505A - Схема дозирования для составов аполипопротеина - Google Patents
Схема дозирования для составов аполипопротеина Download PDFInfo
- Publication number
- RU2014129505A RU2014129505A RU2014129505A RU2014129505A RU2014129505A RU 2014129505 A RU2014129505 A RU 2014129505A RU 2014129505 A RU2014129505 A RU 2014129505A RU 2014129505 A RU2014129505 A RU 2014129505A RU 2014129505 A RU2014129505 A RU 2014129505A
- Authority
- RU
- Russia
- Prior art keywords
- apolipoprotein
- composition
- fixed dose
- body weight
- disease
- Prior art date
Links
- 102000007592 Apolipoproteins Human genes 0.000 title claims abstract 69
- 108010071619 Apolipoproteins Proteins 0.000 title claims abstract 69
- 239000000203 mixture Substances 0.000 title claims abstract 45
- 238000000034 method Methods 0.000 claims abstract 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 24
- 230000037396 body weight Effects 0.000 claims abstract 17
- 201000010099 disease Diseases 0.000 claims abstract 12
- 208000035475 disorder Diseases 0.000 claims abstract 12
- 150000002632 lipids Chemical class 0.000 claims abstract 11
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims abstract 7
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims abstract 7
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims abstract 6
- 239000003599 detergent Substances 0.000 claims abstract 5
- 230000001225 therapeutic effect Effects 0.000 claims abstract 5
- 239000012634 fragment Substances 0.000 claims abstract 4
- 230000000069 prophylactic effect Effects 0.000 claims abstract 4
- 238000011282 treatment Methods 0.000 claims abstract 4
- 206010002388 Angina unstable Diseases 0.000 claims abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract 3
- 208000035150 Hypercholesterolemia Diseases 0.000 claims abstract 3
- 206010020961 Hypocholesterolaemia Diseases 0.000 claims abstract 3
- 208000007814 Unstable Angina Diseases 0.000 claims abstract 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims abstract 3
- 208000010125 myocardial infarction Diseases 0.000 claims abstract 3
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 4
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 4
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims 4
- 241000282412 Homo Species 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 1
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Marine Sciences & Fisheries (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2011905368 | 2011-12-21 | ||
| AU2011905368A AU2011905368A0 (en) | 2011-12-21 | Dosing regime for apolipoprotein formulations | |
| PCT/AU2012/001345 WO2013090978A1 (en) | 2011-12-21 | 2012-11-02 | Dosage regime for apolipoprotein formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017129700A Division RU2776110C2 (ru) | 2012-11-02 | Схема дозирования для составов аполипопротеина |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014129505A true RU2014129505A (ru) | 2016-02-10 |
Family
ID=48667485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014129505A RU2014129505A (ru) | 2011-12-21 | 2012-11-02 | Схема дозирования для составов аполипопротеина |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20140378376A1 (enExample) |
| EP (1) | EP2793913B1 (enExample) |
| JP (2) | JP6144276B2 (enExample) |
| KR (3) | KR20140107536A (enExample) |
| CN (2) | CN104010646A (enExample) |
| AU (1) | AU2012310259C1 (enExample) |
| BR (1) | BR112014014403A8 (enExample) |
| CA (1) | CA2857968A1 (enExample) |
| DK (1) | DK2793913T3 (enExample) |
| ES (1) | ES2955110T3 (enExample) |
| IL (1) | IL233236A0 (enExample) |
| MX (1) | MX377093B (enExample) |
| PL (1) | PL2793913T3 (enExample) |
| RU (1) | RU2014129505A (enExample) |
| SG (1) | SG11201402556RA (enExample) |
| WO (1) | WO2013090978A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9645037B2 (en) | 2011-09-28 | 2017-05-09 | Hunter Engineering Company | Method and apparatus for wheel assembly lateral force measurement |
| CA2857968A1 (en) * | 2011-12-21 | 2013-06-27 | Csl Limited | Dosage regime for apolipoprotein formulations |
| WO2018085890A1 (en) | 2016-11-10 | 2018-05-17 | Csl Limited | Reconstituted high density lipoprotein treatment of myocardial infarction |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61152632A (ja) * | 1984-12-26 | 1986-07-11 | Dai Ichi Seiyaku Co Ltd | 抗動脈硬化剤 |
| US5652339A (en) | 1993-12-31 | 1997-07-29 | Rotkreuzstiftung Zentrallaboratorium | Method of producing reconstituted lipoproteins |
| WO2002038609A2 (en) * | 2000-11-10 | 2002-05-16 | Proteopharma Aps | Apolipoprotein conjugates |
| CA2460787A1 (en) * | 2001-09-28 | 2003-04-03 | Esperion Therapeutics, Inc. | Prevention and treatment of restenosis by local administration of drug |
| BR0310099A (pt) * | 2002-05-17 | 2007-03-20 | Esperion Therapeutics Inc | método para tratar dislipidemia ou uma doença associada com a dislipidemia |
| WO2004010939A2 (en) * | 2002-07-30 | 2004-02-05 | Esperion Therapeutics, Inc. | Methods of using non-human animal apoliprotein a-i protein |
| PE20050438A1 (es) * | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
| CN1870894B (zh) * | 2003-10-20 | 2011-08-10 | 埃斯普里昂治疗公司 | 用于治疗和预防急性冠状动脉综合征的药物制剂、方法和给药方案 |
| WO2007023476A2 (en) * | 2005-08-26 | 2007-03-01 | Cerenis Therapeutics Holding Sa | Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria |
| US20090297577A1 (en) * | 2008-06-02 | 2009-12-03 | Medtronic Vascular, Inc. | Local Delivery of Apolipoproteins and Their Derivatives |
| CA2857968A1 (en) * | 2011-12-21 | 2013-06-27 | Csl Limited | Dosage regime for apolipoprotein formulations |
-
2012
- 2012-11-02 CA CA2857968A patent/CA2857968A1/en not_active Abandoned
- 2012-11-02 CN CN201280063210.4A patent/CN104010646A/zh active Pending
- 2012-11-02 KR KR1020147020291A patent/KR20140107536A/ko not_active Ceased
- 2012-11-02 KR KR1020197019295A patent/KR20190084334A/ko not_active Ceased
- 2012-11-02 JP JP2014547627A patent/JP6144276B2/ja active Active
- 2012-11-02 EP EP12859136.9A patent/EP2793913B1/en active Active
- 2012-11-02 WO PCT/AU2012/001345 patent/WO2013090978A1/en not_active Ceased
- 2012-11-02 CN CN202110675512.8A patent/CN113398245A/zh active Pending
- 2012-11-02 RU RU2014129505A patent/RU2014129505A/ru unknown
- 2012-11-02 DK DK12859136.9T patent/DK2793913T3/da active
- 2012-11-02 KR KR1020207009276A patent/KR102766038B1/ko active Active
- 2012-11-02 PL PL12859136.9T patent/PL2793913T3/pl unknown
- 2012-11-02 US US14/364,764 patent/US20140378376A1/en not_active Abandoned
- 2012-11-02 SG SG11201402556RA patent/SG11201402556RA/en unknown
- 2012-11-02 AU AU2012310259A patent/AU2012310259C1/en active Active
- 2012-11-02 MX MX2014006589A patent/MX377093B/es active IP Right Grant
- 2012-11-02 BR BR112014014403A patent/BR112014014403A8/pt not_active Application Discontinuation
- 2012-11-02 ES ES12859136T patent/ES2955110T3/es active Active
-
2014
- 2014-06-18 IL IL233236A patent/IL233236A0/en active IP Right Grant
-
2016
- 2016-02-26 US US15/054,358 patent/US20160175392A1/en not_active Abandoned
-
2017
- 2017-03-10 JP JP2017045676A patent/JP2017128586A/ja active Pending
-
2023
- 2023-08-14 US US18/449,039 patent/US20240216467A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Barylski et al. | Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality | |
| JP2017528437A5 (enExample) | ||
| RU2017121277A (ru) | Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения | |
| IL250302B (en) | Apoe mimetic peptides and higher potency to clear plasma cholesterol | |
| IL186169A (en) | Charged lipoprotein complexes, pharmaceutical compositions comprising them and their uses | |
| CN110025608A (zh) | 降低心血管疾病风险的方法 | |
| JP2013526545A5 (enExample) | ||
| NZ743714A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| JP2013509435A5 (enExample) | ||
| RS66182B1 (sr) | Stabilne višedozne kompozicije koje sadrže antitelo i konzervans | |
| JP2018507901A5 (ja) | Ｅｔｃ１００２及びエゼチミブを含む固定用量組合せ物及び製剤並びに心血管疾患を処置するか又は心血管疾患のリスクを低減させる方法 | |
| US20160074473A1 (en) | Effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties | |
| Zakiev et al. | HDL-targeting therapeutics: Past, present and future | |
| CN111467351A (zh) | 用于治疗疾病的方法 | |
| RU2014129505A (ru) | Схема дозирования для составов аполипопротеина | |
| CN107530307A (zh) | 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法 | |
| JP2018531605A5 (enExample) | ||
| Atar et al. | Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances | |
| KR20160085795A (ko) | 지방산 니아신 콘주게이트 | |
| RU2009145056A (ru) | Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза | |
| JP2015500840A5 (enExample) | ||
| Maugeais et al. | rHDL administration increases reverse cholesterol transport in mice, but is not additive on top of ezetimibe or cholestyramine treatment | |
| US20160235672A1 (en) | Reconstituted high density lipoproteins composition and uses thereof | |
| RU2014145237A (ru) | Липосомы, содержащие олигопептидные фрагменты основного белка миелина, фармацевтический состав и способ лечения рассеянного склероза | |
| Li et al. | HDL and therapy |